{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:19:04Z","timestamp":1791980344055,"version":"4.4.0"},"reference-count":160,"publisher":"Portland Press Ltd.","issue":"9","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Graft-versus-host disease (GVHD) is a major complication that occurs following allogeneic haematopoietic stem cell transplantation (HSCT) for the treatment of haematological cancers and other blood-related disorders. GVHD is an inflammatory disorder, where the transplanted donor immune cells can mediate an immune response against the recipient and attack host tissues. Despite over 60 years of research, broad-range immune suppression is still used to prevent or treat GVHD, leading to an increased risk of cancer relapse and infection. Therefore, further insights into the disease mechanisms and development of predictive and prognostic biomarkers are key to improving outcomes and reducing GVHD development following allogeneic HSCT. An important preclinical tool to examine the pathophysiology of GVHD and to understand the key mechanisms that lead to GVHD development are preclinical humanised mouse models. Such models of GVHD are now well-established and can provide valuable insights into disease development. This review will focus on models where human peripheral blood mononuclear cells are injected into immune-deficient non-obese diabetic (NOD)-scid-interleukin-2(IL-2)R\u03b3 mutant (NOD-scid-IL2R\u03b3null) mice. Humanised mouse models of GVHD can mimic the clinical setting for GVHD development, with disease progression and tissues impacted like that observed in humans. This review will highlight key findings from preclinical humanised mouse models regarding the role of donor human immune cells, the function of cytokines and cell signalling molecules and their impact on specific target tissues and GVHD development. Further, specific therapeutic strategies tested in these preclinical models reveal key molecular pathways important in reducing the burden of GVHD following allogeneic HSCT.<\/jats:p>","DOI":"10.1042\/bsr20211986","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T04:40:13Z","timestamp":1661143213000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Insights into mechanisms of graft-versus-host disease through humanised mouse models"],"prefix":"10.1042","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-3183","authenticated-orcid":false,"given":"Amal","family":"Elhage","sequence":"first","affiliation":[{"name":"1Illawarra Health and Medical Research Institute, Wollongong NSW 2522, Australia"},{"name":"2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-0742","authenticated-orcid":false,"given":"Chloe","family":"Sligar","sequence":"additional","affiliation":[{"name":"1Illawarra Health and Medical Research Institute, Wollongong NSW 2522, Australia"},{"name":"2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-2586","authenticated-orcid":false,"given":"Peter","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"1Illawarra Health and Medical Research Institute, Wollongong NSW 2522, Australia"},{"name":"2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6242-3944","authenticated-orcid":false,"given":"Debbie","family":"Watson","sequence":"additional","affiliation":[{"name":"1Illawarra Health and Medical Research Institute, Wollongong NSW 2522, Australia"},{"name":"2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-686X","authenticated-orcid":false,"given":"Ronald","family":"Sluyter","sequence":"additional","affiliation":[{"name":"1Illawarra Health and Medical Research Institute, Wollongong NSW 2522, Australia"},{"name":"2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"2022090507303936200_B1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"2022090507303936200_B2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fimmu.2016.00539","article-title":"Danger signals and graft-versus-host disease: current understanding and future perspectives","volume":"7","author":"Toubai","year":"2016","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B3","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol."},{"key":"2022090507303936200_B4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2021","journal-title":"Haematologica"},{"key":"2022090507303936200_B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","article-title":"Allogeneic hematopoietic cell transplantation; the current renaissance","volume":"34","author":"Copelan","year":"2019","journal-title":"Blood Rev."},{"key":"2022090507303936200_B6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","article-title":"Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia","volume":"8","author":"Dickinson","year":"2017","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD","volume":"17","author":"Blazar","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2022090507303936200_B8","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol."},{"key":"2022090507303936200_B9","doi-asserted-by":"publisher","first-page":"761448","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2014-02-514745","article-title":"The biology of graft-versus-host disease: experimental systems instructing clinical practice","volume":"124","author":"Markey","year":"2014","journal-title":"Blood"},{"key":"2022090507303936200_B11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","article-title":"Cytokines and costimulation in acute graft-versus-host disease","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2022090507303936200_B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fphar.2012.00023","article-title":"The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics","volume":"3","author":"Castor","year":"2012","journal-title":"Front. Pharmacol."},{"key":"2022090507303936200_B13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/blood.2019003186","article-title":"Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE\/PBMTC 1202 studies","volume":"135","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"2022090507303936200_B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/tan.12497","article-title":"Insights into the pathogenesis of GvHD: what mice can teach us about man","volume":"85","author":"H\u00fclsd\u00fcnker","year":"2015","journal-title":"Tissue Antigens"},{"key":"2022090507303936200_B16","doi-asserted-by":"publisher","first-page":"596357","DOI":"10.3389\/fphar.2020.596357","article-title":"Use of humanized mouse models to investigate the roles of purinergic signaling in inflammation and immunity","volume":"11","author":"Sluyter","year":"2020","journal-title":"Front. Pharmacol."},{"key":"2022090507303936200_B17","doi-asserted-by":"publisher","first-page":"e8662","DOI":"10.15252\/emmm.201708662","article-title":"Innovations, challenges, and minimal information for standardization of humanized mice","volume":"12","author":"Stripecke","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"2022090507303936200_B18","doi-asserted-by":"publisher","first-page":"723544","DOI":"10.3389\/fimmu.2021.723544","article-title":"GVHD pathogenesis, prevention and treatment: lessons from humanized mouse transplant models","volume":"12","author":"Hess","year":"2021","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B19","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"2022090507303936200_B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tmrv.2018.11.003","article-title":"Peripheral blood or bone marrow stem cells? Practical considerations in hematopoietic stem cell transplantation","volume":"33","author":"Amouzegar","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"2022090507303936200_B21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B22","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022090507303936200_B23","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1182\/blood.2021011975","article-title":"HLA still matters in allogeneic transplants","volume":"138","author":"Bacigalupo","year":"2021","journal-title":"Blood"},{"key":"2022090507303936200_B25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2020.00636","article-title":"Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation","volume":"11","author":"Williams","year":"2020","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B26","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B27","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1097\/HS9.0000000000000581","article-title":"Immunomodulatory therapies for the treatment of graft-versus-host disease","volume":"5","author":"Braun","year":"2021","journal-title":"Hemasphere"},{"key":"2022090507303936200_B28","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"2022090507303936200_B29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"2022090507303936200_B30","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin. Hematol."},{"key":"2022090507303936200_B31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol. Clin."},{"key":"2022090507303936200_B32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1083-8791(99)70011-X","article-title":"Pathophysiologic mechanisms of acute graft-vs.-host disease","volume":"5","author":"Ferrara","year":"1999","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.seminhematol.2005.09.001","article-title":"Pathophysiology of graft-versus-host disease","volume":"43","author":"Ferrara","year":"2006","journal-title":"Semin. Hematol."},{"key":"2022090507303936200_B34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/nm.2242","article-title":"Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R","volume":"16","author":"Wilhelm","year":"2010","journal-title":"Nat. Med."},{"key":"2022090507303936200_B35","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","article-title":"Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines","volume":"90","author":"Hill","year":"1997","journal-title":"Blood"},{"key":"2022090507303936200_B36","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.V83.8.2360.2360","article-title":"Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice","volume":"83","author":"Xun","year":"1994","journal-title":"Blood"},{"key":"2022090507303936200_B37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science"},{"key":"2022090507303936200_B38","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/leu.2012.135","article-title":"Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation","volume":"26","author":"Baron","year":"2012","journal-title":"Leukemia"},{"key":"2022090507303936200_B39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/bmt.2014.293","article-title":"Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation","volume":"50","author":"Nakasone","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1084\/jem.167.2.556","article-title":"Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts","volume":"167","author":"Sprent","year":"1988","journal-title":"J. Exp. Med."},{"key":"2022090507303936200_B41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199602013340501","article-title":"Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation","volume":"334","author":"Goulmy","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"2022090507303936200_B42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1749-6632.1996.tb52655.x","article-title":"IL-12-deficient mice are defective but not devoid of type 1 cytokine responses","volume":"795","author":"Magram","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2022090507303936200_B43","first-page":"591","article-title":"Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells","volume":"138","author":"Singh","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"2022090507303936200_B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2019.08.008","article-title":"CD38(bright)CD8(+) T cells associated with the development of acute GVHD are activated, proliferating, and cytotoxic trafficking cells","volume":"26","author":"Khandelwal","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B45","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/jcm10102050","article-title":"The role of myeloid-derived suppressor cells (MDSCs) in graft-versus-host disease (GVHD)","volume":"10","author":"Demosthenous","year":"2021","journal-title":"J. Clin. Med."},{"key":"2022090507303936200_B46","doi-asserted-by":"publisher","first-page":"697854","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T cells in GVHD therapy","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/bmt.2008.392","article-title":"Cutaneous lymphocyte antigen-positive T cells may predict the development of acute GVHD: alterations and differences of CLA+ T- and NK-cell fractions","volume":"43","author":"Tsuchiyama","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B48","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1182\/blood-2003-03-0957","article-title":"LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease","volume":"103","author":"Petrovic","year":"2004","journal-title":"Blood"},{"key":"2022090507303936200_B49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0952-7915(93)90063-X","article-title":"Homing of naive, memory and effector lymphocytes","volume":"5","author":"Mackay","year":"1993","journal-title":"Curr. Opin. Immunol."},{"key":"2022090507303936200_B50","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J. Immunol."},{"key":"2022090507303936200_B51","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"2022090507303936200_B52","first-page":"209","article-title":"Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model","volume":"7","author":"Dickinson","year":"1991","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B53","first-page":"18","article-title":"Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction","volume":"68","author":"Mowat","year":"1989","journal-title":"Immunology"},{"key":"2022090507303936200_B54","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood-2008-08-172155","article-title":"IL-17 contributes to CD4-mediated graft-versus-host disease","volume":"113","author":"Kappel","year":"2009","journal-title":"Blood"},{"key":"2022090507303936200_B55","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3389\/fimmu.2018.01110","article-title":"Non-coding RNA mediated regulation of allogeneic T cell responses after hematopoietic transplantation","volume":"9","author":"Peltier","year":"2018","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B56","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1172\/JCI78753","article-title":"Mature T cell responses are controlled by microRNA-142","volume":"125","author":"Sun","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2022090507303936200_B57","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1182\/blood-2015-02-627356","article-title":"MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice","volume":"126","author":"Wu","year":"2015","journal-title":"Blood"},{"key":"2022090507303936200_B58","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2014-04-569046","article-title":"MiR-146a regulates the TRAF6\/TNF-axis in donor T cells during GVHD","volume":"124","author":"Stickel","year":"2014","journal-title":"Blood"},{"key":"2022090507303936200_B59","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.4049\/jimmunol.1502152","article-title":"miR-181a expression in donor T cells modulates graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Lee","year":"2016","journal-title":"J. Immunol."},{"key":"2022090507303936200_B60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B61","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2022090507303936200_B62","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbmt.2006.12.441","article-title":"Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease","volume":"13","author":"She","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B63","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","article-title":"Circulating T follicular helper cells with increased function during chronic graft-versus-host disease","volume":"127","author":"Forcade","year":"2016","journal-title":"Blood"},{"key":"2022090507303936200_B64","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.bbmt.2011.05.011","article-title":"Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1\/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031","volume":"17","author":"Rozmus","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B65","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"2022090507303936200_B66","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2022090507303936200_B67","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"2022090507303936200_B68","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2015-09-668251","article-title":"Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells","volume":"127","author":"Kariminia","year":"2016","journal-title":"Blood"},{"key":"2022090507303936200_B69","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archdermatol.2011.226","article-title":"Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses","volume":"147","author":"Martires","year":"2011","journal-title":"Arch. Dermatol."},{"key":"2022090507303936200_B70","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/jcp.26045","article-title":"Humanized mouse models: Application to human diseases","volume":"233","author":"Ito","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"2022090507303936200_B71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nri2017","article-title":"Humanized mice in translational biomedical research","volume":"7","author":"Shultz","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2022090507303936200_B72","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/ni1527","article-title":"Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells","volume":"8","author":"Takenaka","year":"2007","journal-title":"Nat. Immunol."},{"key":"2022090507303936200_B73","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"2022090507303936200_B74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2007.11.001","article-title":"A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene","volume":"126","author":"King","year":"2008","journal-title":"Clin. Immunol."},{"key":"2022090507303936200_B75","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/TP.0b013e3181a5cb07","article-title":"Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice","volume":"87","author":"Ito","year":"2009","journal-title":"Transplantation"},{"key":"2022090507303936200_B76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/cmi.2016.38","article-title":"Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library","volume":"15","author":"Luo","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"2022090507303936200_B77","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1097\/TP.0000000000002756","article-title":"Alloreactive T cells display a distinct chemokine profile in response to conditioning in Xenogeneic GVHD models","volume":"103","author":"Kawasaki","year":"2019","journal-title":"Transplantation"},{"key":"2022090507303936200_B78","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4049\/jimmunol.2000054","article-title":"Early T cell activation metrics predict graft-versus-host disease in a humanized mouse model of hematopoietic stem cell transplantation","volume":"205","author":"Hess","year":"2020","journal-title":"J. Immunol."},{"key":"2022090507303936200_B79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/imm.13374","article-title":"Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanised mouse model","volume":"164","author":"Adhikary","year":"2021","journal-title":"Immunology"},{"key":"2022090507303936200_B80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1042\/CS20201352","article-title":"P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model","volume":"135","author":"Cuthbertson","year":"2021","journal-title":"Clin. Sci."},{"key":"2022090507303936200_B81","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2002-10-3241","article-title":"A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-\/- gammac-\/- double-mutant mice","volume":"102","author":"van Rijn","year":"2003","journal-title":"Blood"},{"key":"2022090507303936200_B82","doi-asserted-by":"publisher","first-page":"e44219","DOI":"10.1371\/journal.pone.0044219","article-title":"Xenogeneic graft-versus-host-disease in NOD-scid IL-2R\u03b3null mice display a T-effector memory phenotype","volume":"7","author":"Ali","year":"2012","journal-title":"PLoS ONE"},{"key":"2022090507303936200_B83","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"key":"2022090507303936200_B84","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cei.13005","article-title":"The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-gamma in a humanized mouse model of graft-versus-host disease","volume":"190","author":"Geraghty","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"2022090507303936200_B85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cellimm.2018.12.001","article-title":"Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease","volume":"336","author":"Geraghty","year":"2019","journal-title":"Cell. Immunol."},{"key":"2022090507303936200_B86","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/CS20191086","article-title":"Increased P2X7 expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease","volume":"134","author":"Cuthbertson","year":"2020","journal-title":"Clin. Sci."},{"key":"2022090507303936200_B87","doi-asserted-by":"publisher","first-page":"e0229724","DOI":"10.1371\/journal.pone.0229724","article-title":"Double-filtered leukoreduction as a method for risk reduction of transfusion-associated graft-versus-host disease","volume":"15","author":"Chun","year":"2020","journal-title":"PLoS ONE"},{"key":"2022090507303936200_B88","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jcyt.2012.09.003","article-title":"Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease","volume":"15","author":"Bruck","year":"2013","journal-title":"Cytotherapy"},{"key":"2022090507303936200_B89","doi-asserted-by":"publisher","first-page":"e0245232","DOI":"10.1371\/journal.pone.0245232","article-title":"Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models","volume":"16","author":"Mashima","year":"2021","journal-title":"PLoS ONE"},{"key":"2022090507303936200_B90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trim.2019.02.003","article-title":"Increased splenic human CD4+:CD8+ T cell ratios, serum human interferon-\u03b3 and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized mice","volume":"54","author":"Geraghty","year":"2019","journal-title":"Transpl. Immunol."},{"key":"2022090507303936200_B91","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/pbc.25347","article-title":"Impact of very early CD4+\/CD8+ T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation","volume":"62","author":"Huttunen","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"2022090507303936200_B92","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00277-017-2999-5","article-title":"Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines","volume":"96","author":"Budde","year":"2017","journal-title":"Ann. Hematol."},{"key":"2022090507303936200_B93","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2018.04.016","article-title":"Comprehensive analysis of the activation and proliferation kinetics and effector functions of human lymphocytes, and antigen presentation capacity of antigen-presenting cells in xenogeneic graft-versus-host disease","volume":"24","author":"Kawasaki","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B94","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/ajt.14116","article-title":"A novel xenogeneic graft-versus-host disease model for investigating the pathological role of human CD4+ or CD8+ T cells using immunodeficient NOG mice","volume":"17","author":"Ito","year":"2017","journal-title":"Am. J. Transplant."},{"key":"2022090507303936200_B95","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1196\/annals.1447.009","article-title":"Humanized mice for the study of type 1 diabetes and beta cell function","volume":"1150","author":"King","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2022090507303936200_B96","doi-asserted-by":"publisher","first-page":"e1314425","DOI":"10.1080\/2162402X.2017.1314425","article-title":"Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects","volume":"6","author":"Ehx","year":"2017","journal-title":"Oncoimmunology"},{"key":"2022090507303936200_B97","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.humimm.2009.06.001","article-title":"Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc","volume":"70","author":"Vlad","year":"2009","journal-title":"Hum. Immunol."},{"key":"2022090507303936200_B98","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/bmt.2011.93","article-title":"Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD\/SCID\/\u03b3c\u2212 mouse model","volume":"47","author":"Gregoire-Gauthier","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B99","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1172\/JCI91138","article-title":"PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells","volume":"127","author":"Ni","year":"2017","journal-title":"J. Clin. Invest."},{"key":"2022090507303936200_B100","doi-asserted-by":"publisher","first-page":"e90088","DOI":"10.1172\/jci.insight.90088","article-title":"Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells","volume":"2","author":"Picarda","year":"2017","journal-title":"JCI Insight"},{"key":"2022090507303936200_B101","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J. Clin. Investig."},{"key":"2022090507303936200_B102","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bbmt.2018.10.007","article-title":"In vitro Th17-polarized human CD4+ T cells exacerbate xenogeneic graft-versus-host disease","volume":"25","author":"Delens","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B103","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbmt.2015.01.006","article-title":"Role of Natural Killer Cells in Intravenous Immunoglobulin\u2013Induced Graft-versus-Host Disease Inhibition in NOD\/LtSz-scidIL2rg\u2212\/\u2212 (NSG) Mice","volume":"21","author":"Gregoire-Gauthier","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B104","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.4049\/jimmunol.176.2.1266","article-title":"Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation\/differentiation of pathogenic T cells","volume":"176","author":"Trenado","year":"2006","journal-title":"J. Immunol."},{"key":"2022090507303936200_B105","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"2022090507303936200_B106","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-10-3347","article-title":"Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease","volume":"17","author":"Beres","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2022090507303936200_B107","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","article-title":"Absence of regulatory T-cell control of Th1 and Th17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"2022090507303936200_B108","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"2022090507303936200_B109","doi-asserted-by":"publisher","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"key":"2022090507303936200_B110","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2337\/db19-0525","article-title":"Low-dose interleukin-2 combined with rapamycin led to an expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells and prolonged human islet allograft survival in humanized mice","volume":"69","author":"Hu","year":"2020","journal-title":"Diabetes"},{"key":"2022090507303936200_B111","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/cmi.2016.30","article-title":"Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions","volume":"14","author":"Gu","year":"2017","journal-title":"Cell Mol. Immunol."},{"key":"2022090507303936200_B112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/ajt.13456","article-title":"Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells","volume":"16","author":"Dijke","year":"2016","journal-title":"Am. J. Transplant."},{"key":"2022090507303936200_B113","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fimmu.2020.00181","article-title":"Interleukin-27 enforces regulatory T cell functions to prevent graft-versus-host disease","volume":"11","author":"Le","year":"2020","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B114","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jcyt.2013.07.009","article-title":"Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease","volume":"16","author":"Parmar","year":"2014","journal-title":"Cytotherapy"},{"key":"2022090507303936200_B115","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/j.1600-6143.2011.03558.x","article-title":"Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease","volume":"11","author":"Hippen","year":"2011","journal-title":"Am. J. Transplant."},{"key":"2022090507303936200_B116","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"B\u00e9zie","year":"2019","journal-title":"Blood Adv."},{"key":"2022090507303936200_B117","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3389\/fimmu.2020.01496","article-title":"IL-34 actions on FOXP3(+) Tregs and CD14(+) monocytes control human graft rejection","volume":"11","author":"B\u00e9zie","year":"2020","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B118","doi-asserted-by":"publisher","first-page":"eabi9591","DOI":"10.1126\/science.abi9591","article-title":"KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19","volume":"376","author":"Li","year":"2022","journal-title":"Science"},{"key":"2022090507303936200_B119","doi-asserted-by":"publisher","first-page":"1880046","DOI":"10.1080\/2162402X.2021.1880046","article-title":"Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect","volume":"10","author":"Janikashvili","year":"2021","journal-title":"Oncoimmunology"},{"key":"2022090507303936200_B120","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fimmu.2019.00183","article-title":"GM-CSF promotes the expansion and differentiation of cord blood myeloid-derived suppressor cells, which attenuate xenogeneic graft-vs-host disease","volume":"10","author":"Park","year":"2019","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B121","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jsbmb.2018.12.013","article-title":"Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells","volume":"188","author":"Vanherwegen","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"2022090507303936200_B122","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"2022090507303936200_B123","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jcyt.2013.10.012","article-title":"Optimization of the therapeutic efficacy of human umbilical cord blood-mesenchymal stromal cells in an NSG mouse xenograft model of graft-versus-host disease","volume":"16","author":"Jang","year":"2014","journal-title":"Cytotherapy"},{"key":"2022090507303936200_B124","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3389\/fimmu.2019.00619","article-title":"Comparison of mesenchymal stromal cells from different origins for the treatment of graft-vs-host-disease in a humanized mouse model","volume":"10","author":"Gr\u00e9goire","year":"2019","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B125","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/s41598-021-81916-y","article-title":"Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation","volume":"11","author":"Tago","year":"2021","journal-title":"Sci. Rep."},{"key":"2022090507303936200_B126","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1089\/scd.2011.0413","article-title":"Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model","volume":"21","author":"Gregoire-Gauthier","year":"2012","journal-title":"Stem Cells Dev."},{"key":"2022090507303936200_B127","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B128","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12185-013-1399-4","article-title":"Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I\/II study","volume":"98","author":"Muroi","year":"2013","journal-title":"Int. J. Hematol."},{"key":"2022090507303936200_B129","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B130","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","article-title":"Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation","volume":"21","author":"Zhao","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2022090507303936200_B131","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","article-title":"Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study","volume":"103","author":"Muroi","year":"2016","journal-title":"Int. J. Hematol."},{"key":"2022090507303936200_B132","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bmt.2016.317","article-title":"Good responses but high TRM in adult patients after MSC therapy for GvHD","volume":"52","author":"Salmenniemi","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B133","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/imt-2017-0117","article-title":"Immune modulation by apoptotic dental pulp stem cells in vivo","volume":"10","author":"Laing","year":"2018","journal-title":"Immunotherapy"},{"key":"2022090507303936200_B134","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13287-019-1287-9","article-title":"The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease","volume":"10","author":"Zhao","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"2022090507303936200_B135","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12056","article-title":"Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease","volume":"172","author":"Tobin","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"2022090507303936200_B136","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-018-0151-8","article-title":"Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease","volume":"32","author":"Kim","year":"2018","journal-title":"Leukemia"},{"key":"2022090507303936200_B137","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.ymthe.2019.05.007","article-title":"Alpha-1 antitrypsin-expressing mesenchymal stromal cells confer a long-term survival benefit in a mouse model of lethal GvHD","volume":"27","author":"Geiger","year":"2019","journal-title":"Mol. Ther."},{"key":"2022090507303936200_B138","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/imcb.12251","article-title":"Pharmacological blockade of the CD39\/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease","volume":"97","author":"Geraghty","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"2022090507303936200_B139","doi-asserted-by":"publisher","first-page":"8343","DOI":"10.3390\/ijms22158343","article-title":"Purinergic signalling in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease","volume":"22","author":"Cuthbertson","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2022090507303936200_B140","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.intimp.2019.04.037","article-title":"The A(2A) receptor agonist CGS 21680 has beneficial and adverse effects on disease development in a humanised mouse model of graft-versus-host disease","volume":"72","author":"Geraghty","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"2022090507303936200_B141","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjh.12378","article-title":"Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody","volume":"162","author":"Hatano","year":"2013","journal-title":"Br. J. Haematol."},{"key":"2022090507303936200_B142","doi-asserted-by":"publisher","first-page":"785774","DOI":"10.3389\/fimmu.2021.785774","article-title":"Daratumumab prevents experimental xenogeneic graft-versus-host disease by skewing proportions of T cell functional subsets and inhibiting T cell activation and migration","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B143","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3389\/fimmu.2017.00756","article-title":"Targeting the human T-cell inducible COStimulator molecule with a monoclonal antibody prevents graft-vs-host disease and preserves graft vs leukemia in a xenograft murine model","volume":"8","author":"Burlion","year":"2017","journal-title":"Front. Immunol."},{"key":"2022090507303936200_B144","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/bloodadvances.2019000286","article-title":"Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation","volume":"3","author":"Iliopoulou","year":"2019","journal-title":"Blood Adv."},{"key":"2022090507303936200_B145","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1158\/1535-7163.MCT-20-0093","article-title":"Pharmacologic properties and preclinical activity of sasanlimab, a high-affinity engineered anti-human PD-1 antibody","volume":"19","author":"Al-Khami","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"2022090507303936200_B146","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","article-title":"Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation","volume":"131","author":"Soiffer","year":"2018","journal-title":"Blood"},{"key":"2022090507303936200_B147","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood-2011-07-368027","article-title":"Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes","volume":"119","author":"Hippen","year":"2012","journal-title":"Blood"},{"key":"2022090507303936200_B148","doi-asserted-by":"publisher","first-page":"e00276","DOI":"10.1016\/j.heliyon.2017.e00276","article-title":"Combination of IL-10 and IL-2 induces oligoclonal human CD4 T cell expansion during xenogeneic and allogeneic GVHD in humanized mice","volume":"3","author":"Abraham","year":"2017","journal-title":"Heliyon"},{"key":"2022090507303936200_B149","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2014.11.004","article-title":"IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion","volume":"156","author":"Abraham","year":"2015","journal-title":"Clin. Immunol."},{"key":"2022090507303936200_B150","doi-asserted-by":"publisher","first-page":"e0179239","DOI":"10.1371\/journal.pone.0179239","article-title":"NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination","volume":"12","author":"Kametani","year":"2017","journal-title":"PLoS ONE"},{"key":"2022090507303936200_B151","doi-asserted-by":"publisher","first-page":"e3289","DOI":"10.1371\/journal.pone.0003289","article-title":"Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells","volume":"3","author":"Carroll","year":"2008","journal-title":"PLoS ONE"},{"key":"2022090507303936200_B152","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/ajt.15298","article-title":"R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease","volume":"19","author":"Fowler","year":"2019","journal-title":"Am. J. Transplant."},{"key":"2022090507303936200_B153","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41409-021-01363-1","article-title":"Itacitinib prevents xenogeneic GVHD in humanized mice","volume":"56","author":"Courtois","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"2022090507303936200_B154","doi-asserted-by":"publisher","first-page":"eaai8269","DOI":"10.1126\/scitranslmed.aai8269","article-title":"Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function","volume":"9","author":"Betts","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2022090507303936200_B155","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1158\/1078-0432.CCR-20-4725","article-title":"Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results","volume":"27","author":"Pidala","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2022090507303936200_B156","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/ajt.16505","article-title":"Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis","volume":"21","author":"Ehx","year":"2021","journal-title":"Am. J. Transplant."},{"key":"2022090507303936200_B157","doi-asserted-by":"publisher","first-page":"39.e10","DOI":"10.1016\/j.exphem.2012.09.005","article-title":"GSK3 inhibition prevents lethal GVHD in mice","volume":"41","author":"Klamer","year":"2013","journal-title":"Exp. Hematol."},{"key":"2022090507303936200_B158","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.2147\/JIR.S323054","article-title":"Human amniotic mesenchymal stem cells inhibit aGVHD by regulating balance of Treg and T effector cells","volume":"14","author":"Gao","year":"2021","journal-title":"J Inflamm Res."},{"key":"2022090507303936200_B159","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2014-10-603449","article-title":"Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo","volume":"125","author":"Parmar","year":"2015","journal-title":"Blood"},{"key":"2022090507303936200_B160","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/cei.13145","article-title":"Infusion of ex-vivo expanded human TCR-\u03b1\u03b2+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease","volume":"193","author":"Achita","year":"2018","journal-title":"Clin. Exp. Immunol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20211986\/936760\/bsr-2021-1986c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20211986\/936760\/bsr-2021-1986c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T08:29:17Z","timestamp":1676449757000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/42\/9\/BSR20211986\/231673\/Insights-into-mechanisms-of-graft-versus-host"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":160,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20211986","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9]]},"published":{"date-parts":[[2022,9]]},"article-number":"BSR20211986"}}